Interim results were presented at the American Academy of Ophthalmology (AAO) meeting in New Orleans USA, November 11-14 2017. LIGHTSITE I enrolled 30 dry AMD subjects who were randomized (1:1) to PBM treatment or sham treatment. “We have examined the interim data...Drs. Merry and Dotson resigned from the board of directors of Lumithera Inc. on April 3rd 2017. Both physicians no longer have an active management role within Lumithera Inc. They both however remain firm believers in the science and clinical application of...Dr. Graham Merry will be presenting his abstract this May at ARVO 2016. Improvements in vision and reduction of drusen have now been seen with Photobiomodulation (PBM) in over 40 eyes in this latest study. This is exciting news confirming significant disease...Dr. Graham Merry attended EURETINA 2015 in Nice, France. Several productive meetings were held to further consolidate upcoming European clinical trial sites.